Lunai Bioworks Inc. (NASDAQ:LNAI) Short Interest Down 47.7% in June

Lunai Bioworks Inc. (NASDAQ:LNAI) saw a significant drop in short interest in June. As of June 30th, there was short interest totaling 150,195 shares, a drop of 47.7% from the June 15th total of 287,256 shares. Approximately 3.3% of the company’s shares are short sold. Based on an average trading volume of 4,793,299 shares, the short-interest ratio is currently 0.0 days.

Institutional Investors Weigh In On Lunai Bioworks

An institutional investor recently bought a new stake in Lunai Bioworks stock. Millennium Management LLC acquired a new stake in Lunai Bioworks Inc. (NASDAQ:LNAI) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 202,629 shares of the company’s stock, valued at approximately $288,000. Millennium Management LLC owned about 0.87% of Lunai Bioworks as of its most recent SEC filing. 71.41% of the stock is currently owned by institutional investors.

Lunai Bioworks Stock Down 3.4%

NASDAQ:LNAI traded down $0.10 during mid-day trading on Thursday, hitting $2.88. 62,754 shares of the stock traded hands, compared to its average volume of 1,645,833. Lunai Bioworks has a 52 week low of $1.21 and a 52 week high of $28.80. The stock has a market capitalization of $13.05 million, a price-to-earnings ratio of -7.20 and a beta of 0.37. The firm’s 50 day moving average is $2.83 and its two-hundred day moving average is $3.91.

Lunai Bioworks (NASDAQ:LNAI) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.10) earnings per share (EPS) for the quarter. The business had revenue of $0.02 million for the quarter.

Wall Street Analysts Forecast Growth

LNAI has been the subject of several analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Lunai Bioworks in a research note on Wednesday, July 8th. Wall Street Zen upgraded Lunai Bioworks to a “sell” rating in a research report on Saturday, May 23rd. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Lunai Bioworks currently has a consensus rating of “Sell”.

About Lunai Bioworks

Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection.